Pelvic Angiography in Non-Responders to Phosphodiesterase-5 Inhibitors (PANPI)

Erectile Dysfunction Clinical Trial

— PANPI  

Official title:

Pelvic Angiography in Non-Responders to Phosphodiesterase-5 Inhibitors (PANPI)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00574184
• Other study ID #: 200513528
• Status: Completed
• Phase: N/A
• First received: December 13, 2007
• Last updated: October 27, 2017
• Start date: August 2005
• Est. completion date: March 2008

Study information

• Verified date: March 2008
• Source: University of California, Davis
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The specific aim of this pilot study is to describe the angiographic prevalence and pattern of internal pudendal artery (and associated inflow vessel) atherosclerosis in patients with erectile dysfunction who are non-responsive to PDE-5 inhibitors (i.e., Viagra) who are referred for clinically-indicated cardiac catheterization.

Description:

The specific aim of this study is to determine if the deep penile arteries can be seen angiographically from the iliac arteries to delineate penile vasculature. Significant obstructive atherosclerotic disease of the deep penile arteries may be present in impotent males. The etiology of erectile dysfunction is multifactorial and may involve vascular disease, endocrine disorders, neurologic disease, prescription medications, psychological issues and/or trauma in any given patient. Vascular disease in patients with erectile dysfunction may be due to trauma, congenital anomalies, or atherosclerosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: March 2008
• Est. primary completion date: March 2008
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Male patients

• at least 50 years

• erectile dysfunction

• dissatisfaction with their use of a phosphodiesterase-5 inhibitor

• coronary artery disease (or at risk for coronary artery disease)

• undergoing diagnostic cardiac catheterization or patients with peripheral vascular disease undergoing peripheral arteriography

Exclusion Criteria:

• Patients who respond favorably to phosphodiesterase-5 inhibitors

• known non-vascular etiologies of their erectile dysfunction

• probable neurogenic erectile dysfunction due to radiation injury, surgery, or transurethral resection of the prostate

• calculated GFR < 60 ml/min/1.73 m2 will also be excluded

• disease that necessitates complex percutaneous intervention will be excluded per the investigators discretion

Related Conditions & MeSH terms

• Erectile Dysfunction

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of California, Davis

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Distal aortography with iliofemoral run-off will be performed to evaluate disease in the common and internal iliac arteries.		During Procedural Cath
Secondary	Selective angiography of the internal pudendal artery (and accessory pudendal artery if present) will be performed bilaterally.		During Procedural Cath
Secondary	Intra-arterial nitroglycerin (or papaverine or tolazoline if nitroglycerin is contraindicated) will be used to facilitate angiographic visualization of the internal pudendal and penile arteries.		During Procedural Cath

External Links

•   UC Davis Health System